Evidence map›Paper›PMID 26511493›Full record

ArticleJournal of neuro-oncology2016

Association between RAD 51 rs1801320 and susceptibility to glioblastoma.

S Franceschi, S Tomei, C M Mazzanti, F Lessi, P Aretini, M La Ferla, V De Gregorio, F Pasqualetti, K Zavaglia, G Bevilacqua and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Journal of oncology · 2019
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

S FranceschiDepartment of Surgical, Molecular and Ultrastructural Pathology, University Hospital of Pisa, Via Roma 57, 56126, Pisa, PI, Italy. sara.franceschi@fondazionepisascienza.org.
S TomeiSidra Medical and Research Center, P.O. Box 26999, Doha, Qatar.
C M MazzantiPisa Science Foundation, Via Panfilo Castaldi 2, 56121, Pisa, PI, Italy.
F LessiPisa Science Foundation, Via Panfilo Castaldi 2, 56121, Pisa, PI, Italy.
P AretiniPisa Science Foundation, Via Panfilo Castaldi 2, 56121, Pisa, PI, Italy.
M La FerlaPisa Science Foundation, Via Panfilo Castaldi 2, 56121, Pisa, PI, Italy.
V De GregorioPisa Science Foundation, Via Panfilo Castaldi 2, 56121, Pisa, PI, Italy.
F PasqualettiRadiotherapy Unit, University Hospital of Pisa, Via Roma 67, 56126, Pisa, PI, Italy.
K ZavagliaDepartment of Surgical, Molecular and Ultrastructural Pathology, University Hospital of Pisa, Via Roma 57, 56126, Pisa, PI, Italy.
G BevilacquaDepartment of Surgical, Molecular and Ultrastructural Pathology, University Hospital of Pisa, Via Roma 57, 56126, Pisa, PI, Italy.
A G NaccaratoDepartment of Surgical, Molecular and Ultrastructural Pathology, University Hospital of Pisa, Via Roma 57, 56126, Pisa, PI, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma is the most common and aggressive malignant primary brain tumor. Despite decades of research and the advent of new therapies, patients with glioblastoma continue to have a very poor prognosis. Radiation therapy has a major role as adjuvant treatment for glioblastoma following surgical resection. Many studies have shown that polymorphisms of genes involved in pathways of DNA repair may affect the sensitivity of the cells to treatment. Although the role of these polymorphisms has been investigated in relation to response to radiotherapy, their role as predisposing factors to glioblastoma has not been clarified yet. In the present study, we evaluated the association between polymorphisms in DNA repair genes, namely: XRCC1 rs25487, XRCC3 rs861539 and RAD51 rs1801320, with the susceptibility to develop glioblastoma. Eighty-five glioblastoma patients and 70 matched controls were recruited for this study. Data from the 1000 Genomes Project (98 Tuscans) were also downloaded and used for the association analysis. Subjects carrying RAD51 rs1801320 GC genotype showed an increased risk of glioblastoma (GC vs GG, χ(2) = 10.75; OR 3.0087; p = 0.0010). The C allele was also significantly associated to glioblastoma (χ(2) = 8.66; OR 2.5674; p = 0.0032). Moreover, RAD51 rs1801320 C allele increased the risk to develop glioblastoma also when combined to XRCC1 rs25487 G allele and XRCC3 rs861539 C allele (χ(2) = 6.558; p = 0.0053).

Indexed as

DNA RepairPolymorphism, Single NucleotideAgedBrain NeoplasmsDNA-Binding ProteinsFemaleGene FrequencyGenetic Association StudiesGenetic Predisposition to DiseaseGlioblastomaHumansMaleMiddle AgedRad51 RecombinaseRisk FactorsX-ray Repair Cross Complementing Protein 1DNA-Binding ProteinsRAD51 protein, humanRad51 RecombinaseX-ray Repair Cross Complementing Protein 1X-ray repair cross complementing protein 3XRCC1 protein, humanDNA repair genesGlioblastomaPolymorphismsRAD51Risk

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.